|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2006-11-23
|
|
pubmed:abstractText |
To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determine the safety profile of the virus, look for evidence of biological activity, and identify a dosing schedule for later studies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CoffinRobert SRS,
pubmed-author:CoombesR CharlesRC,
pubmed-author:DavisCeri JCJ,
pubmed-author:GrahamNicola JNJ,
pubmed-author:GrovesNatashaN,
pubmed-author:GuestPeter JPJ,
pubmed-author:HarringtonKevin JKJ,
pubmed-author:HuJennifer C CJC,
pubmed-author:JamesNicholas DND,
pubmed-author:LoveColin ACA,
pubmed-author:McNeishIainI,
pubmed-author:MedleyLouise CLC,
pubmed-author:MichaelAgnieszkaA,
pubmed-author:NuttingChristopher MCM,
pubmed-author:PandhaHardev SHS,
pubmed-author:ShorrockClaire ACA,
pubmed-author:SimpsonJulieJ,
pubmed-author:SteinerJanJ,
pubmed-author:StevenNeil MNM,
pubmed-author:WrightDennisD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6737-47
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17121894-Adult,
pubmed-meshheading:17121894-Aged,
pubmed-meshheading:17121894-Aged, 80 and over,
pubmed-meshheading:17121894-Antibodies, Antinuclear,
pubmed-meshheading:17121894-Biopsy,
pubmed-meshheading:17121894-Breast Neoplasms,
pubmed-meshheading:17121894-Carcinoma,
pubmed-meshheading:17121894-Colorectal Neoplasms,
pubmed-meshheading:17121894-Cytokines,
pubmed-meshheading:17121894-Female,
pubmed-meshheading:17121894-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:17121894-Head and Neck Neoplasms,
pubmed-meshheading:17121894-Humans,
pubmed-meshheading:17121894-Male,
pubmed-meshheading:17121894-Melanoma,
pubmed-meshheading:17121894-Middle Aged,
pubmed-meshheading:17121894-Neoplasms,
pubmed-meshheading:17121894-Oncolytic Virotherapy,
pubmed-meshheading:17121894-Oncolytic Viruses,
pubmed-meshheading:17121894-Recombinant Proteins,
pubmed-meshheading:17121894-Simplexvirus,
pubmed-meshheading:17121894-Skin Neoplasms,
pubmed-meshheading:17121894-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
|
|
pubmed:affiliation |
Department of Cancer Medicine, Imperial College School of Medicine, Royal Marsden Hospital, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
